BIOR - חוב כולל להון Biora Therapeutics, Inc

This chart illustrates the debt load of Biora Therapeutics (BIOR), which stands at 0.00, confirming the company's reliance on external financing due to a lack of profitable products. The business model relies on the efficiency of the NaviCap system for targeted release in the intestine. The growth strategy is based on licensing the unique platform, allowing the company to monetize patents without establishing its own manufacturing plants.

To build a resilient portfolio, I evaluate the total liabilities-to-equity ratio, which determines the business's dependence on external financing and its default risks. Given the early-stage clinical trials of Biora Therapeutics (BIOR), where device expansion costs are high, the company's financial dependency trend on this chart demonstrates a balance between debt and capitalization to ensure survival until deals with pharma behemoths are reached.